Biopartners Presents Three Year Safety And Efficacy Data For Sustained Release Recombinant Human Growth Hormone (LB03002) At ESPE 2008

Biopartners GmbH presented three year safety and efficacy trial data in children with growth hormone deficiency (GHD) for its once-a-week, sustained release recombinant human growth hormone (SR-hGH; LB03002) at the Annual Meeting of the European Society for Paediatric Endocrinology in Istanbul.

More: continued here

Filed under: Endocrinology on October 1st, 2008